Syridex Bio
Syridex Bio is an impact-driven, life sciences-focused firm investing in therapies that accelerate global health equity by addressing the needs of underserved communities. Syridex Bio was founded on the belief that everyone deserves the opportunity to live a healthy life. For too long, deep inequities have persisted across our pharmaceutical, biotechnology, and medical systems. Despite increased public attention on the problem in recent years, progress remains far too slow. At Syridex Bio, we are addressing this gap in the market by strategically investing in therapies that treat diseases disproportionately affecting minoritized communities. By financing the development of drugs and treatments addressing the world’s greatest health disparities, we are convinced that we can accelerate health equity globally and achieve strong financial returns for our investors.
Syridex Bio is a venture capital and growth equity firm focused on life sciences, specifically investing in therapeutics, biotechnology, and drug development that address health disparities in underserved communities.
Princeton, New Jersey, United States
Venture Capital and Private Equity Principals
venture capital, growth equity
healthcare, life sciences, biotechnology, pharmaceuticals
—
—
4
2022
healthcare · life sciences, biotechnology, pharmaceuticals, therapeutics, drug development, health equity
Done
Prospects
No prospects linked to this account.
Outreach History
Outreach sequencing tables are not yet in Supabase.